ViroCell Biologics, a specialist viral vector CDMO for cell and gene therapy clinical trials, entered into a partnership with University College London (UCL) to advance a chimeric antigen receptor (CAR) T-cell therapy for relapsed pediatric acute lymphoblastic leukemia (ALL). Genetically modified CAR T-cells targeting CD19 have shown impressive outcomes in relapsed/refractory ALL. However, 50% of responding patients will relapse either due to evolution of CD19 negative disease or early loss o...